Κατεύθυνση Κλινικοπαθολογοανατομική θεώρηση των νεοπλασιών του ανθρώπου
Library of the School of Health Sciences

2016-10-03

2016

Αντωνιάδου Δημητρούλα

Α. Χ. Λάζαρης

Γενετικό υπόβαθρο και νεότερα δεδομένα στη στοχευμένη θεραπεία του καρκίνου του παγκρέατος

Greek

Cancer is essentially a genetic disease caused by the accumulation of somatic
mutations in oncogenes and tumor suppressor genes. Over the past decade, the
rapid advance of technology for sequencing and bioinformatics has led to an
explosion of sequencing studies of the cancer genome, significantly expanding
our knowledge. Several of these studies of cancer genomes have focused on
pancreatic tumors, which cover a wide spectrum from benign cysts to deadly
cancers. Genetic alterations in which tumors of the pancreas are mounted, is
also varied. The aim is to deepen the understanding of oncogenesis in the
pancreas and the juxtaposition of numerous new possibilities for promising new
diagnostic and therapeutic agents.
Patients with pancreatic cancer have a poor prognosis with 6.4 months median
survival and a 5 year survival of less than 5%. Despite treatment with known
drugs, e.g. gemcitabine, survival does not exceed six months. It is hoped that
beneficial results may be obtained by the use of guided immunotherapy against
molecular targets. Passive immunotherapy may have a role in the treatment in
combination with radiochemotherapy which, when administered alone, destroys the
immune system together with the tumor cells. It includes mainly therapies
targeting kinases, treatments against DNA repair genes, histone deacetylases,
microRNAs, and stromal tissue
84
elements of pancreatic tumor. Also specific immunotherapies, such as vaccines
(whole cell recombinant, peptide, and dendritic cell vaccines), cell therapy
and immunotherapy targeting tumor cells stem are being investigated. In the
future, treatments will likely include personalized medicine, adapted for many
molecular therapeutic targets in multiple pathogenic pathways. Ιt is hoped that
in the short term the research will lead to a practical clinical outcome for
all patients suffering from pancreatic cancer.

Στοχευουσα θεραπεία, Παράγοντες κινδύνου, Γονιδιακό υπόβαθρο, Πορογενές ασενοκαρκίνωμα, Γενετικές μεταβολές

No

0

Yes

151

102

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/1310437